Moderna Inc
F:0QF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Moderna Inc
F:0QF
|
US |
|
I
|
Ishii Iron Works Co Ltd
TSE:6362
|
JP |
|
Transocean Ltd
NYSE:RIG
|
CH |
|
C
|
Compagnie Financiere Richemont SA
SWB:RIT1
|
CH |
|
Pixelworks Inc
NASDAQ:PXLW
|
US |
|
Hitachi Ltd
F:HIA1
|
JP |
|
D
|
Dai-ichi Life Holdings Inc
SWB:QHH
|
JP |
|
Sequans Communications SA
NYSE:SQNS
|
FR |
|
T
|
Teladoc Health Inc
SWB:4LL
|
US |
|
L
|
Lundin Mining Corp
XBER:GXD
|
CA |
|
H
|
Huatai Securities Co Ltd
SWB:206H
|
CN |
|
B
|
Budweiser Brewing Company APAC Ltd
OTC:BDWBY
|
HK |
|
E
|
Enbridge Inc
LSE:0KTI
|
CA |
Moderna Inc
Moderna is a biotechnology company that develops medicines based on messenger RNA, or mRNA. Instead of making drugs in the traditional way, it designs mRNA instructions that tell the body’s cells to produce specific proteins, which can train the immune system or help treat disease. Its best-known products are vaccines, and its pipeline also includes treatments for infectious diseases, cancer, and rare conditions. The company sells its products mainly to governments, health systems, clinics, and other healthcare buyers, depending on the medicine and market. It earns money through product sales, supply agreements, and partnerships with larger drug companies and research organizations. A lot of Moderna’s value comes from the fact that it owns the technology and development know-how behind mRNA medicines, not just a single product. What makes Moderna different is its role as a platform company in a field that is still relatively new. It can use the same core mRNA approach to design multiple medicines, which gives it a common scientific engine across many programs. That makes Moderna more like a technology-driven drug developer than a traditional pharmaceutical company built around a few long-established pills or chemical drugs.
Moderna is a biotechnology company that develops medicines based on messenger RNA, or mRNA. Instead of making drugs in the traditional way, it designs mRNA instructions that tell the body’s cells to produce specific proteins, which can train the immune system or help treat disease. Its best-known products are vaccines, and its pipeline also includes treatments for infectious diseases, cancer, and rare conditions.
The company sells its products mainly to governments, health systems, clinics, and other healthcare buyers, depending on the medicine and market. It earns money through product sales, supply agreements, and partnerships with larger drug companies and research organizations. A lot of Moderna’s value comes from the fact that it owns the technology and development know-how behind mRNA medicines, not just a single product.
What makes Moderna different is its role as a platform company in a field that is still relatively new. It can use the same core mRNA approach to design multiple medicines, which gives it a common scientific engine across many programs. That makes Moderna more like a technology-driven drug developer than a traditional pharmaceutical company built around a few long-established pills or chemical drugs.
Revenue beat: Moderna reported first-quarter revenue of $400 million, above guidance, and said the strong start keeps it on track to deliver up to 10% revenue growth in 2026.
Litigation hit: Net loss was $1.3 billion, driven mainly by an $878 million charge tied to the Arbutus and Genevant settlement; excluding that item, net loss would have been $0.5 billion.
Cost discipline: Adjusted cash costs fell 26% year over year in Q1, and the company reiterated its full-year target of about $4.2 billion.
Pipeline momentum: Moderna highlighted EU approvals for mCOMBRIAX and mNEXSPIKE, a U.S. PDUFA date of August 5 for mRNA-1010, and a new Phase III start for Intismeran in high-risk Stage I lung cancer.
Cash position: The company ended Q1 with $7.5 billion in cash and investments and said its 2026 guidance does not assume any use of its remaining $0.9 billion undrawn credit facility.
